Quick Answer
Two recent capsule programs make the same point from different directions. Lonza's Capsugel® Enprotect® is a ready-to-use enteric capsule built from HPMC and H…
What the Recent Delivery Work Actually Shows
Cyclic Peptide Wholesale Pept Cost Three sources set the factual baseline, and each one stops well short of a bioavailability claim.
Enprotect. ar Capsugel product page describes a ready-to-use enteric capsule using HPMC and HPMC-AS polymers with a Coni-Snap secure closure, protecting acid-sensitive APIs and allowing targeted intestinal delivery. The stated acid resistance is up to pH 6.0, and the capsule eliminates the need for post-filling coating. That is a dosage-form specification: it says where the shell is designed to survive, not what happens to a peptide after release.
Bilayer capsules for ileal targeting. ar Capsugel knowledge-center summary of Millet et al., European Journal of Pharmaceutical Sciences 2026;224:107601, describes a system combining an HPMC- and pullulan-based inner layer with an outer ethylcellulose layer containing sodium alginate as a pore former — diffusion control plus environmentally responsive function in one dosage form. The study evaluated how formulation composition and manufacturing parameters affect gastric resistance, permeabilidad, disintegration and release, ne identificó concentraciones específicas ar alginato ne ar nkohi ar curado da produjeron perfiles liberación retardada consistentes ko ya puntería ileum distal. ge 'nar estudio parámetros proceso ne formulación. hingi informa ar absorción in vivo.
Yoho ya niveles GLP — 1 'ba̲ts'i. ar Fronteras he̲'mi dige 'nar formulación lípidos mäs cápsulas entéricas ge ar mäs Hmunts'i peptíde-relevante ja ya hñu. ya autores formularon exenatida análoga GLP — 1 komongu 'nar par iones hidrofóbicos (HIP) ja 'nar formulación basada jar lípidos ko excipientos potenciadores ar permeación, gem'bu̲ ingeniería gelatina yá HPMC — AS cápsulas entéricas modificado pa requisitos ntsuni hontho da cumplieron ya requisitos liberación retardada USP. Ar cáscara ar cápsula ar capsula da Hinte Ntsuni kontra ya nkohi gástricas; ya gotas lípidas protegen kontra ya proteasas intestinales. The authors describe the result as an in vitro proof of concept and state plainly that in vivo pharmacokinetic and pharmacodynamic studies, extended stability, and long-term formulation–capsule compatibility work remain to be done.
lei ga̲tho, the three sources cover three different layers of the same problem — shell, matriz, and peptide-in-vehicle — and none of them demonstrates improved oral bioavailability. That is the correct scope to carry into any internal discussion.
Why the Sequence Alone Cannot Decide Oral Feasibility
A 2026 Frontiers review of oral peptide barriers states the physicochemical case compactly: peptides are relatively large, polar and charged, which produces low permeability through the mucus layer and the underlying epithelium; they are susceptible to gastric and intestinal proteases; they tend to aggregate; Ne ya tso̲kwa menudo inestables maneras complican nte sólida sólida ar dosificación. ar revisión pone biodisponibilidad oral inherente pa mäs xingu ya compuestos tso̲kwa continuación 1%.
Esas propiedades ya hechos jar za̲ ár nthe̲ ar secuencia, Ne propagan. Carga neta ne NTHEGE carga determinan nu'bu̲ 'nar péptido cruzará 'nar red mucosidad cargada negativamente wa unir bí nu'ä. Hidrofobicidad establece tanto afinidad ar membrana komongu ar riesgo ar auto-asociación jar concentraciones relevantes formulación. Ya nt'ot'e ar susceptibilidad ya proteasa — sitios dibásicos pa enzimas similares ar tripsina, Residuos aromáticos pa ar quimotripsina, Ya residuos N — terminales pa aminopeptidasas — jäts'i Temu̲ enzimas luminales atacarán 'me̲t'o ne ho 'nar nyokwi estabilizador gana mäs. Aggregation propensity determines whether the concentration needed for dosing is even reachable in the chosen vehicle.
This is why a clean certificate of analysis cannot settle oral feasibility. HPLC purity is a relative area percentage; it tells you how much of the UV-absorbing material is the main peak. It does not tell you the counterion form, the residual water, the net peptide content, or how the molecule behaves when it meets gastric acid, bile salts and pancreatic enzymes in sequence. 'nar péptido to da 98% pure and still fail at the first barrier.
The review also explains why the field has not stalled despite sub-1% bioavailability. Structural modifications that raise potency, metabolic stability and half-life allow therapeutic effect at low single-digit exposure. Oral semaglutide is the established example; the review also cites the macrocyclic PCSK9 inhibitor enlicitide and the IL-23 receptor antagonist icotrokinra as late-stage or clinically successful cases, and Chugai’s cyclic peptide Luna18, which reached 21%–47% oral bioavailability in preclinical models. The threshold moved because the molecule was engineered for it — and that engineering is a synthesis decision.
Protection Has to Be Layered, Not Singular
The two-tier GLP-1 study is worth reading closely because it shows the layers being stacked deliberately rather than discovered by accident.
Exenatide remaining after 60 min in α-chymotrypsin (7.50 d, room temperature, HPLC readout). Unformulated exenatide degraded completely within minutes; the hydrophobic ion pair in lipid-based formulation retained roughly 80%. The difference between the sodium caprate (C10) and no-C10 arms was not statistically significant. In vitro proteolysis protection only — not permeability, absorption or bioavailability. Source: Dumont et al., Front. Drug Deliv. 2026;6:1770094.
At the molecular level, the authors converted exenatide acetate into a hydrophobic ion pair. Log P measurements moved from −2.9 ± 0.3 for the acetate to 0.1 ± 0.2 ne 0.9 ± 0.2 for the SLS and DOC ion pairs at a 1:4 molar ratio, and the DOC pair was carried forward. That is a chemistry decision made to change the molecule’s partitioning behavior — the kind of choice that belongs in the synthesis and salt-selection phase, not in a formulation group working from a fixed API.
At the formulation level, the HIP was loaded into a lipid-based formulation with permeation-enhancing excipients. The lipid phase does two jobs: it keeps the peptide out of direct contact with intestinal proteases, and it co-localizes the peptide with the permeation enhancer at the epithelial surface. ar barrier review notes that co-localization is exactly where many oral dosage forms fail — if release occurs in the wrong compartment, or the formulation dilutes, or the enhancer separates from the API, translatability collapses.
At the dosage-form level, the customized enteric capsule provides gastric protection and prevents premature dilution of the lipid phase in gastric fluid, which would otherwise displace the peptide from its protective environment. Liberación péptido ne potenciador ar coordinado jar sitio absorción intestinal.
Ar observación xí instructiva jar he̲'mi ge 'nar hallazgo formulación ho̲ntho bí thogi visible nu'bu̲ ar péptido ne ar vehículo ar estudian ga̲tho: nzäm'bu hingi maa plazo mostró degradación dependiente ar formulación, Ko ar formación ar impureza mäs mextha pa solubilizado EXE — HIP da pa acetato EXE suspendido, Particularmente jar mpat'i ambiente. Jar dätä hnini físico ar API — njäts'i kontra suspensión — cambió trayectoria degradación. 'nar equipo mi caracterizado ho̲ntho ar polvo liofilizado habría 'be̲di 'me̲hna totalmente, Ne habría descubierto mäs ya'bu̲, Ja 'nar etapa xingu mäs hmädi.
Ya 'yot'u̲he̲'mi 'nehe señalan 'nar riesgo oxidación aterrado jar ar secuencia: Metionina 14 Ne triptófan 25 are susceptible to oxidation in lipid matrices containing peroxides, aldehydes or metal ions. Their cyclic voltammetry method could not identify the most effective antioxidant, so they recommend fresh lipid excipients and control of light and oxygen exposure instead. That is a concrete example of a sequence feature driving a formulation and handling requirement.
Terminal-Ileum Targeting: Why Site and Transit Matter
The distal ileum is a meaningful target for reasons that differ by modality. It is an absorption region for certain drugs and emerging modalities, including biologics and nucleic acid-based therapies, and targeted delivery there has the potential to enhance local efficacy while minimizing systemic exposure and off-target effects, as the Capsugel summary i. It also carries the highest concentration of Peyer’s patches, which matters for mucosal immune targeting, as the Nefecon imaging study reports.
Hitting it reliably is the hard part. The region has a dynamic physiological environment and a relatively short transit time, and the summary identifies reliable release there as one of the greatest remaining challenges in oral drug delivery.
The best available benchmark comes from a human imaging study of the Nefecon capsule, a targeted-release budesonide formulation approved for primary IgA nephropathy that acts on galactose-deficient IgA1 overproduction in Peyer’s patches. The study used test capsules reproducing Nefecon’s delayed-release function, with caffeine as a marker for capsule opening (it appears rapidly in saliva after release) and magnetic resonance imaging with black iron oxide to locate the capsule and visualize dispersion. In vitro dissolution confirmed the test capsules matched Nefecon’s release characteristics. In 10 ar 12 volunteers the capsule opened in the distal ileum; in the other two it opened just past the ileocecal junction. The authors present this as favorable against the high variability reported in other published imaging studies of delayed-release formulations targeting the gut.
That result is a distribution, not a point. Ten of twelve is a strong outcome for the field, and it still means a release specification written against a single nominal time is under-specified. If your target site is the distal ileum, the specification has to describe acceptable behavior across a transit distribution — including the tail of subjects who arrive late — and the assay panel has to be able to distinguish a capsule that opened in the wrong place from a peptide that degraded after it opened in the right one. Note also the scope: this is a 12-volunteer imaging study of a budesonide formulation, and its numbers should not be transferred to a peptide program as an expected success rate.
The Label Is Part of the Experiment
Every transport or biodistribution experiment on a peptide requires a way to see it, and the way you see it is a chemical modification. The common options are fluorescent dyes, radiolabels such as 3H, 14C or 125I, stable isotopes, biotin, and various chemical tags. Each carries a different perturbation profile: a bulky fluorophore can dominate the surface properties of a small peptide, a radiolabel substitutes an atom, biotin adds a large hydrophobic-bicyclic ligand that can bind streptavidin-like proteins in unexpected places.
ar microfluidic intestinal-barrier work states the risk directly. Because the microscopy readout requires a fluorescent reporter, and because modification could potentially alter the transport behavior of biologics — especially for smaller peptides — the authors argue it is paramount to select dyes that minimally interfere with the physicochemical properties of the biologic, for example fluorophores shown to have minimal propensity for lipid membrane interaction. They cite work in which fluorophore labeling of a cell-penetrating peptide significantly altered the mode and degree of biomembrane interaction.
That is a measurement artifact with the same magnitude as the effect being measured. A labeled peptide that binds membranes more avidly than its parent will look more permeable in a cell model and less available in a luminal stability assay, and neither result reflects the unlabeled molecule.
The practical rule: choose the label that minimally perturbs the property you are measuring, then confirm that labeled and unlabeled species behave comparably in the assay that matters before trusting the readout. For a permeability study, that means comparing transport of labeled versus unlabeled peptide in the same model. For a stability study, it means confirming the label does not change the degradation profile. For a biodistribution study, it means an orthogonal quantification method — LC-MS/MS of the unlabeled peptide, for instance — against the imaging signal. If the labeled and unlabeled species diverge, the label is the experiment, not the peptide.
Reading the Data: Which Assay Answers Which Question
A failed oral peptide experiment produces a symptom, not a diagnosis. The table below maps common symptoms to assays that can separate their causes. It is a starting framework, not a validated decision tree; the specific methods and acceptance criteria belong to your product and should be justified against ICH Q2(R2) and your own development stage.
|
Symptom |
Likely causes |
Assays that discriminate |
|---|---|---|
|
Low plasma exposure after oral dosing |
Poor capsule release; peptide degradation in gastric or intestinal fluid; xí hñets'i'i permeabilidad epitelial; adsorción ma cápsula wa ya tubo; aggregation |
disolución yoho ya etapas ko muestreo específico ar sitio; simulada nzäm'bu fluidos gástricos ne intestinales ko LC — MS identificación fragmentos; permeabilidad aparente ja 'nar modelo epitelial ko ne hinda mucos; balance masa jar aparato ar cápsula ne ar dosificación; dispersión tsibi dinámica wa cromatografía tamaño — exclusión pa agregación |
|
mextha ar formación impurezas ja ar formulación |
degradación química (oxidation, hidrólisis, �); interacción péptido-excipiente; efectos ar dätä físico (njäts'i vs. suspensión) |
Degradación forzada ko identificación fragmento ya MS yá MS; estudio compatibilidad excipiente jar 'mui nthe almacenamiento prevista; comparación ar API solubilizada versus suspendida jar nkohi idénticas |
|
Capsula gi xoki jar segmento equivocado |
composición cáscara wa espesor ar recubrimiento; parámetros ar curado; variabilidad tránsito |
In vivo tsita ko 'nar marcador nt'o̲t'e; in vitro liberación ja 'nar modelo disolución multi — compartimentos; estudio parámetros dige ar mpat'i ne ar humedad ar curado |
|
señal 'mui pe ntsoni ausente |
artefacto ar etiqueta; interferencia ensayo; péptido inactivo 'mefa xta etiquetar |
cuantificación hinda etiquetar paralelo (LC — MS YÁ MS); ensayo nt'ot'e ortogonal jar hñei etiquetados ne hinda etiquetar |
|
variabilidad lote lote jar rendimiento entrega |
Contraataque wa diferencias contenido petídicos neto; residual Ar fábrica ar péptidos dehe; Dätä agregación; tamaño partícula |
contenido contracontador ya cromatografía ión; péptido neto ya CHN wa análisis aminoácidos cuantitativo; Karl Fischer contenido ar dehe; NTHEGE tamaño partícula |
Vocabulario analítico importa nuwa. Pureza ge 'nar porcentaje área ir nge ya HPLC ne hingi hmä otho dige Tengu masa peptídica 'bu̲i 'bui. Identity is an orthogonal structural confirmation — mass spectrometry plus a second technique. Content, n, is a mass-balance quantity that accounts for counterion, disolventes ar dehe ne residuales. Online Peptides Stability is a study design with defined conditions and timepoints, not a single measurement. Assay suitability is about format, matrix and controls. A single HPLC purity number cannot adjudicate a delivery failure, and treating it as if it could is one of the more common ways a program spends a quarter chasing the wrong variable.
ICH Q2(R2), � 1 Nobyembre 2023, is the relevant anchor for the analytical side. Its specificity/selectivity section calls for representative data — chromatograms, electropherograms, spectra — with relevant components labelled, and for investigation of suitable discrimination at an appropriate level, such as resolution of the two closest-eluting components in a critical separation. That is the standard a delivery-relevant method should meet: it must be able to see the degradation product you are looking for, not just the main peak.
From Synthesis Data to Delivery Decisions
The reframing is straightforward once the barriers are laid out in order. The certificate of analysis, the chromatogram, the counterion form, the solubility and aggregation data, and the stability timepoints are not release paperwork that follows a synthesis campaign. They are the inputs that constrain every downstream choice, and they should be specified with the delivery route in view from the start.
A workable sequence runs like this: Purchase Peptides
-
Define the target GI site and the release window. Distal ileum, proximal small intestine, or stomach changes the shell, the coating, and the transit assumptions the specification is written against.
-
Derive stability and permeability requirements from the sequence. Identify protease-susceptibility motifs, oxidation-prone residues, aggregation-prone segments, and the charge and hydrophobicity profile. These set the minimum stabilization chemistry and the permeability strategy.
-
Select stabilization chemistry. Non-canonical residues, ciclización, N — metilación, �, or ion pairing — each addresses a specific liability identified in step 2, and each is a synthesis decision with its own analytical consequences. Isotope Labeled Peptides Factory
-
Select the formulation. Lipid phase, permeation enhancer, protease inhibitor, pH modulator. Confirm the peptide’s physical state in that vehicle and its compatibility with the excipients at the intended storage condition.
-
Select the release system. Capsule shell, coating, or bilayer architecture, with the release specification written against a transit distribution rather than a nominal time.
-
Define the assay panel that proves each step. Dissolution with site-specific sampling, stability-indicating HPLC, orthogonal identity confirmation, content and counterion, and the labeled-versus-unlabeled comparison for any imaging or transport readout.
The critical discipline is recognizing when a sequence change invalidates a prior formulation decision. Swap a residue to improve potency and you may change the charge, the aggregation propensity, the log P, or the oxidation liability — and the ion pair, the lipid vehicle, and the capsule release profile may all need to be re-derived. A sequence version that is not change-controlled is the most common cause of a formulation result that cannot be reproduced. Treat the sequence and its modification history as an immutable record, and re-run the affected formulation work whenever that record changes.
This is also where the two-tier GLP-1 study earns its place as a model. The authors did not hand a finished API to a formulation group. They changed the salt form to change partitioning, studied the physical state in the vehicle, identified oxidation liabilities from the sequence, and built the capsule around the formulation’s needs. The synthesis and the delivery were one program.
Where MOL Changes Fits
The framework above calls for an upstream partner that can produce the peptide and the characterization data with the delivery route already in view. MOL Changes is a peptide research and development organization that states it provides multiple viable research avenues for the advancement of peptide science, and its stated capabilities map onto the early steps of that sequence.
On synthesis, the company states it has mastered solid-phase, fase líquida, combinado líquido-sólido, inverse solid-phase and microbial fermentation methods, with customized sequences up to 200 amino acids and scale from milligrams to kilograms. On modification, it lists cyclization, c, glicosilación, n, i, �, Etiquetado ar isótopo, fluorescent labeling and biotinylation among more than 300 modifying groups — the chemistries that appear in steps 2 ne 3 above. On quality, it states that production is maintained in a supplier-described Class 100 clean room from the first experimental step through packaging, with automated monitoring of sterilization, air pressure, humidity, temperature and dust particles, and that QC covers HPLC, MS, pureza, content, endotoxin, sterility, pH and moisture with batch-specific data.
Two of those offerings are directly relevant to the measurement problems discussed earlier. Fluorescent and isotope labeling services are the same modifications that can perturb a peptide’s transport behavior; a labeling partner that reports the labeled species’ analytical profile alongside the parent gives you the data to check comparability. Counterion choice is a related lever — the company lists TFA as default, with acetate, chloride or ammonium salt exchange available — but the log P shift in the two-tier study, from −2.9 ± 0.3 for exenatide acetate to 0.9 ± 0.2 for its DOC ion pair, came from hydrophobic ion pairing, not from that kind of salt exchange.
To be clear about scope: MOL Changes states these as its own synthesis, nthokwi, scale and QC capabilities. It does not perform the capsule engineering, imaging studies or clinical work described in the sources above, and nothing here implies otherwise. The connection is narrower and more useful — the synthesis and characterization choices that determine whether a downstream delivery program has a workable starting point are made at this stage, and they are better made with the delivery route already specified.
Disclosure: MOL Changes is a commercial peptide synthesis and modification provider and has a commercial interest in the quality and documentation standards discussed in this article.
References and Retrieval Notes
Sources were retrieved on 27 � 2026. Figures and outcomes are reported at the scope of the cited study and should not be generalized to other molecules, formulations or patient populations without confirmation.
-
Capsugel® Enprotect® capsules, página ar producto, Lonza yá Capsugel: https://www.capsugel.com/pharmaceutical-solutions/hard-empty-capsules/enprotect-capsules. resistencia ar ácido declarada asta ar pH 6.0; hingi recubrimiento post — llenado.
-
Capsugel conocimiento — made resumen ar Millet E, Vandenbroucke SST, O 'Shea JP, Griffin BT, Jannin V. diseño ne evaluación parámetros proceso sistemas cápsula bicapa pa entrega droga ileal dirigida. European Journal of Pharmaceutical Sciences 2026;224:107601. doi:10.1016/j.ejps.2026.107601: https://www.capsugel.com/knowledge-center/pharma/capsules/targeted-ileal-delivery-Enprotect-capsules. Estudio ar parámetros ar formulación ne ar proceso; hingi absorción in vivo reportada ja ar resumen.
-
Dumont et al. A two-tier protection strategy for oral delivery of GLP-1 peptides: lipid-based formulation combined with enteric capsules. fronteras jar entrega ar drogas 2026: https://www.frontiersin.org/articles/10.3389/fddev.2026.1770094/full. In vitro prueba jar mfeni jar; in vivo PK yá PD ne nzäm'bu ya'bu̲ plazo identificada ir nge ya autores komongu 'be̲fi futuro.
-
Khalid et jar. revisión ya barreras entrega peptidos orales. fronteras jar entrega ar drogas 2026: https://www.frontiersin.org/journals/drug-delivery/articles/10.3389/fddev.2026.1809842/full. ndo'yo biodisponibilidad sub — 1% ge 'nar hmä jar za̲ ár nthe̲ revisión dige mäs xingu ya compuestos, hingi 'nar hmädi nxo̲ge; ndo'yo 21% — 47% pa Luna18 ar preclínico.
-
estudio tsita distal — ileum Nefecon, Resumen ar PubMed: https://pubmed.ncbi.nlm.nih.gov/38723178/. Ma yoho ya voluntarios; capsule opened in the distal ileum in 10 and just past the ileocecal junction in 2.
-
Weller et al. Microfluidic intestinal epithelial barrier model. h 2022;965200: https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2022.965200/full. Fluorophore perturbation noted for small peptides.
-
Brown, Whitehead & Mitragotri. Materials for oral delivery of proteins and peptides. Nature Reviews Materials 5:127–148: https://www.nature.com/articles/s41578-019-0156-6. Review of physiological barriers.
-
ICH Q2(R2), Validation of Analytical Procedures, final version adopted 1 Nobyembre 2023: https://database.ich.org/sites/default/files/ICH_Q2(R2)_Guideline_2023_1130.pdf.
-
ICH Q1A(R2), Stability Testing of New Drug Substances and Products, via FDA: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products.
-
MOL Changes: company site, síntesis péptidos personalizada, ntsa̲ peptídicos. Company-stated capabilities only.
